Conversations with Cancer Experts Series
Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?
Dr. Ajai Chari MD
Professor of Medicine
Director of Myeloma Program
University of California San Francisco
Dr. Ajai Chari MD
Professor of Medicine
Director of Myeloma Program
University of California San Francisco
Ajai Chari: DREAMM 7 and 8
Dr Ravi Vij and Dr. Ajay Chari discussed the latest updates on Blenrep (Belantamab Mafadotin) and DREAMM 7 and 8 studies presented at ASCO focusing on the study design, primary endpoint, and survival curves. Dr. Chari highlighted the impressive median PFS months in the experimental arms of these two studies. Dr Ravi Vij and Dr Chari discussed the challenges and opportunities in optimizing Blenrep dosing and scheduling for myeloma patients, with a focus on patient tolerance and potential infection risks. Finally, Ravi Vij and Dr Chari discussed the latest developments in BCMA-based treatments for multiple myeloma, including dose reduction strategies, frequency of administration of Blenrep, and the role of CAR-T therapy.
Outline
DreaMM 7 and 8 for multiple myeloma treatment.
# Dr. Ajay Chari discusses dream 7 and 8 studies at ASCO, providing updates on Blenrep.
Belantamab-Vd in the DreMM 7 trial for relapsed myeloma, showing improved PFS with triplet regimen.
# Dr. Ajay Chari highlights the unique study design, with triplet therapy and de-escalation based on progression.
# The primary endpoint shows a median PFS of 36 months in the experimental arm, compared to 13.4 months in the control arm.
# Dr. Ajay Chari highlights the importance of lenalidomide refractoriness in the analysis of the ASCO presentation, noting that the hazard ratio is still significant, indicating a 70% improvement in likelihood of progression for Blenrep backbone in lenalidomide refractory patients.
# In the high-risk cytogenetics group, Blenrep performed similarly to standard risk with a PFS of 36.6 months versus 33.2 months, suggesting that Blenrep may do well for these high-risk patients.
ASCO presentation Belantamab-Pd in the DreaMM 8 Study
# Dr. Ajay Chari highlights the importance of DreaMM 8 study in addressing unmet needs in double refractory multiple myeloma patients.
# Belantamab POM Dex is studied in DreaMM 8 as experimental arm, with dose intensity reduced to mitigate cumulative toxicity.
# Dr. Ajay Chari Relapsed myeloma patients with high risk features had improved PFS with Belantamab targeting BCMA.
The efficacy and safety of Belantamab in multiple myeloma patients, with a focus on subgroups and toxicity profile.
# Dr. Ajay Chari highlights the benefits of adding belantamab for refractory patients, with improved PFS and OS across subgroups.
# Dr. Ajay Chari notes the need to salvage transplant-ineligible, older patients with daratumumab refractory disease, with limited data on truly double refractory population.
# Dr. Ajay Chari highlights the unique infection profile of Belantamab, with lower infection rates compared to other BCMA targeting therapies.
# Dr. Ajay Chari discusses the efficacy and tolerability of Belantamab, with the ability to skip doses or adjust the schedule for patients with ocular issues.
Optimizing dosing and schedule for Belantamab in multiple myeloma treatment.
# Dr. Ajay Chari discusses challenges with accelerated approval of new myeloma drugs, including prioritizing efficacy over safety and toxicity.
# Dr. Ajay Chari suggests moving away from dose escalation studies at the bedside and towards more standardized induction and maintenance dosing.
# Dr. Ajay Chari suggests starting with lower dose and frequency for BCMA treatments, then adjusting based on patient response.
# Dr. Ajay Chari prioritizes car T therapy over antibody drug conjugate and other treatments, citing single best efficacy.
BCMA therapy for myeloma, including infection risks and retreatment options.
# Dr. Ajay Chari discusses potential benefits and risks of using CAR-T cell therapy in myeloma patients.
# Dr. Ajay Chari highlights the challenges of retreatment in myeloma, including the difficulty of re-using drugs after progression.
# Dr. Ajay Chari that belantamab could be a viable option for retreatment in myeloma, particularly for patients who are infection-prone or elderly.
#. Dr. Ajay Chari discusses potential challenges with targeting BCMA in multiple myeloma, including T cell exhaustion and genomic loss of CMA.
# Dr. Ajay Chari suggests that ADCs may be a viable alternative to BCMA bispecifics, offering respite for T cell recovery.
Dr Ravi Vij and Dr. Ajay Chari discussed the latest updates on Blenrep (Belantamab Mafadotin) and DREAMM 7 and 8 studies presented at ASCO focusing on the study design, primary endpoint, and survival curves. Dr. Chari highlighted the impressive median PFS months in the experimental arms of these two studies. Dr Ravi Vij and Dr Chari discussed the challenges and opportunities in optimizing Blenrep dosing and scheduling for myeloma patients, with a focus on patient tolerance and potential infection risks. Finally, Ravi Vij and Dr Chari discussed the latest developments in BCMA-based treatments for multiple myeloma, including dose reduction strategies, frequency of administration of Blenrep, and the role of CAR-T therapy.
Outline
DreaMM 7 and 8 for multiple myeloma treatment.
# Dr. Ajay Chari discusses dream 7 and 8 studies at ASCO, providing updates on Blenrep.
Belantamab-Vd in the DreMM 7 trial for relapsed myeloma, showing improved PFS with triplet regimen.
# Dr. Ajay Chari highlights the unique study design, with triplet therapy and de-escalation based on progression.
# The primary endpoint shows a median PFS of 36 months in the experimental arm, compared to 13.4 months in the control arm.
# Dr. Ajay Chari highlights the importance of lenalidomide refractoriness in the analysis of the ASCO presentation, noting that the hazard ratio is still significant, indicating a 70% improvement in likelihood of progression for Blenrep backbone in lenalidomide refractory patients.
# In the high-risk cytogenetics group, Blenrep performed similarly to standard risk with a PFS of 36.6 months versus 33.2 months, suggesting that Blenrep may do well for these high-risk patients.
ASCO presentation Belantamab-Pd in the DreaMM 8 Study
# Dr. Ajay Chari highlights the importance of DreaMM 8 study in addressing unmet needs in double refractory multiple myeloma patients.
# Belantamab POM Dex is studied in DreaMM 8 as experimental arm, with dose intensity reduced to mitigate cumulative toxicity.
# Dr. Ajay Chari Relapsed myeloma patients with high risk features had improved PFS with Belantamab targeting BCMA.
The efficacy and safety of Belantamab in multiple myeloma patients, with a focus on subgroups and toxicity profile.
# Dr. Ajay Chari highlights the benefits of adding belantamab for refractory patients, with improved PFS and OS across subgroups.
# Dr. Ajay Chari notes the need to salvage transplant-ineligible, older patients with daratumumab refractory disease, with limited data on truly double refractory population.
# Dr. Ajay Chari highlights the unique infection profile of Belantamab, with lower infection rates compared to other BCMA targeting therapies.
# Dr. Ajay Chari discusses the efficacy and tolerability of Belantamab, with the ability to skip doses or adjust the schedule for patients with ocular issues.
Optimizing dosing and schedule for Belantamab in multiple myeloma treatment.
# Dr. Ajay Chari discusses challenges with accelerated approval of new myeloma drugs, including prioritizing efficacy over safety and toxicity.
# Dr. Ajay Chari suggests moving away from dose escalation studies at the bedside and towards more standardized induction and maintenance dosing.
# Dr. Ajay Chari suggests starting with lower dose and frequency for BCMA treatments, then adjusting based on patient response.
# Dr. Ajay Chari prioritizes car T therapy over antibody drug conjugate and other treatments, citing single best efficacy.
BCMA therapy for myeloma, including infection risks and retreatment options.
# Dr. Ajay Chari discusses potential benefits and risks of using CAR-T cell therapy in myeloma patients.
# Dr. Ajay Chari highlights the challenges of retreatment in myeloma, including the difficulty of re-using drugs after progression.
# Dr. Ajay Chari that belantamab could be a viable option for retreatment in myeloma, particularly for patients who are infection-prone or elderly.
#. Dr. Ajay Chari discusses potential challenges with targeting BCMA in multiple myeloma, including T cell exhaustion and genomic loss of CMA.
# Dr. Ajay Chari suggests that ADCs may be a viable alternative to BCMA bispecifics, offering respite for T cell recovery.
